Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine - Martín, Iván; Navarro, Blanca; Serrano, Alicia; Villamón, Eva; Calabuig, Marisa; Solano, Carlos; Chaves, Felipe Javier; Yagüe, Nuria; Orts, Maribel; Amat, Paula; Fuentes, Azahara; Seda, Enrique; et al. (Annals of hematology, 2020)
Keywords: Aged; Aged, 80 and over; Azacitidine - administration & dosage; Chromosome Deletion; Chromosomes, Human, Pair 7 - genetics; Chromosomes, Human, Pair 7 - metabolism; Cyclin-Dependent Kinase Inhibitor p15 - genetics; Cyclin-Dependent Kinase Inhibitor p15 - metabolism; Cytogenetics; Disease-Free Survival; DNA Methylation - drug effects; DNA, Neoplasm - genetics; DNA, Neoplasm - metabolism; Female; GTPase-Activating Proteins - genetics; GTPase-Activating Proteins - metabolism; Hematology; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - mortality; Male; Medicine; Medicine & Public Health; Middle Aged; Mutation; Myelodysplastic syndromes; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - genetics; Myelodysplastic Syndromes - metabolism; Myelodysplastic Syndromes - mortality; Oncology; Original Article; Promoter Regions, Genetic; Survival Rate; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; Promoter methylation; Gene mutations; Azacitidine; Platelet doubling; Acute myeloid leukemia; Myelodysplastic syndromes